---
title: "Aspen: The drug replacing semaglutide has been approved in South Africa for chronic weight management"
description: "On October 13th, it was reported that Aspen Pharmacare announced that the South African Health Products Regulatory Authority has approved its once-weekly prescription treatment drug Mounjaro for an ad"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260858575.md"
published_at: "2025-10-13T08:51:36.000Z"
---

# Aspen: The drug replacing semaglutide has been approved in South Africa for chronic weight management

> On October 13th, it was reported that Aspen Pharmacare announced that the South African Health Products Regulatory Authority has approved its once-weekly prescription treatment drug Mounjaro for an additional indication, to be used as an adjunct to diet and exercise for chronic weight management, effective from October

On October 13th, it was reported that Aspen Pharmacare announced that the South African Health Products Regulatory Authority has approved its once-weekly prescription treatment drug Mounjaro for an additional indication, to be used as an adjunct to diet and exercise for chronic weight management, effective from October

### Related Stocks

- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 礼来第四季度营收为 192.9 亿美元，同比增长 43%。预计全年营收为 800 亿至 830 亿美元，市场预期为 777.1 亿美元 | 礼来第四季度营收为 192.9 亿美元，同比增长 43%。预计全年营收为 800 亿至 830 亿美元，市场预期为 777.1 亿美元。 | [Link](https://longbridge.com/en/news/274805260.md) |
| 3.5 亿首付款、总额达 85 亿美元！信达生物与礼来合作布局肿瘤免疫新药研发 | 信达生物与礼来达成突破性合作，将联合开发肿瘤及免疫新药。此次交易预付款 3.5 亿美元，总额最高达 85 亿美元。双方摒弃传统授权，采用从零开始的共同研发模式，标志着中国药企创新力获全球顶尖药企深度认可，开启全球战略协作新篇章。 | [Link](https://longbridge.com/en/news/275269682.md) |
| Madrigal 制药｜8-K：2025 财年 Q4 营收 3.21 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276330350.md) |
| 新研究发现，场外交易药物在美国人健康管理中起到了核心作用 | 一项发表在《JAMA Network Open》上的新研究显示，62% 的美国成年人在过去一周内使用了至少一种药物，其中 46% 使用了非处方药（OTC）。研究强调了非处方药和处方药的共同使用，以满足各种健康需求。主要发现表明，像对乙酰氨基 | [Link](https://longbridge.com/en/news/276267527.md) |
| 斥资 185 亿美元牵手石药集团后，阿斯利康每股收益预增双位数 | 阿斯利康预计 2026 年每股收益将实现两位数增长，肿瘤药物销售强劲有望抵消糖尿病药物专利到期影响。公司近期以高达 185 亿美元引入石药集团长效肽技术，加速布局 GLP-1 减肥药市场。尽管面临美国药价政策调整，公司通过协议获得关税豁免。 | [Link](https://longbridge.com/en/news/275425282.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.